Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,501–1,600 of 2,162
Binneboessel, S., on behalf of the COVIP study group, Bruno, R. R., et al. (2022) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-221579 · Cited by 3
“Patients receiving cytokine absorption therapy had a higher SOFA-score (9 [7–13] vs. 8 [5–10]; p = 0.02) at admission and were more frail prior to hospitalisation (CFS 5 [3–6] vs. 3 [2–5]; p < 0.001, Fig.”
InfluentialBiosimilar, Biobetter, and Biosuperior Therapeutic Proteins
Pathak, A., Singh, S. P., Tiwari, A., Tripathi, A. M., Jahan, T., & Singh, D. B. (2023) · Springer eBooks · doi:10.1007/978-981-19-8249-1_12 · Cited by 5
Review of the Clinical Trial Failures of Nanomedicines Targeting Cancer
Mukherjee, S., Honkala, A. T., & Rolnik, B. M. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i2.2607 · Cited by 4
New drug discovery and development
da Silva, M. F., dos Santos, A. B. S. F., Batista, V. D. M., Rodrigues, É. E. D. S., de Araújo‐Júnior, J. X., & da Silva‐Júnior, E. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91817-6.00017-6 · Cited by 4
Safety of biologic agents for the management of rheumatic diseases during pregnancy
D’Gama, J. D., & Bermas, B. L. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001014 · Cited by 5
Catamero, D., Benito, P. B., Shenoy, S., Doyle, M., Fowler, J., Kobos, R., Banerjee, A., & Kruyswijk, S. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151621 · Cited by 3
CD8+ T Cell Biology in Cytokine Storm Syndromes
Sekine, T., Galgano, D., Casoni, G. P., Meeths, M., Cron, R. Q., & Bryceson, Y. T. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_10 · Cited by 4
A facility for laboratory mice with a natural microbiome at Charité – Universitätsmedizin Berlin
Drude, N., Nagel-Riedasch, S., Rosshart, S. P., Diefenbach, A., Diederich, K., Duerr, C. U., Harms, C., Heppner, F. L., Kolesnichenko, M., Lewejohann, L., et al. (2024) · Lab Animal · doi:10.1038/s41684-024-01474-4 · Cited by 3
Outsourcing Clinical Trials Outside of the US
Dezfuli, M. (2017) · Pharmaceutical Regulatory Affairs Open Access · doi:10.4172/2167-7689.1000194 · Cited by 3
“In a Phase I clinical trial, eight adult volunteers were administered a drug via intravenous infusion [9], with six of them facing incredibly adverse side effects within an hour of the administration of the drug.”
BackgroundHoang, B. X., & Han, B. (2021) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000263 · Cited by 5
“inappropriate therapeutic interventions [5,6].”
Ferreira, M., Sécher, T., Heuzé‐Vourc'h, N., & Reckamp, K. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060912 · Cited by 5
“In general, monoclonal Abs, including immunomodulatory Abs, have proven to be well tolerated [35].”
BackgroundHuman IgG Glycosylation in Inflammation and Inflammatory Disease
Mimura, Y., & Jefferis, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00047-x · Cited by 4
Garzone, P. D., & Wang, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00011-2 · Cited by 3
Basics of immunooncology and immunotherapy in oncology
Логинова, Е. Н., Lyalyukova, E. A., Nadey, E. V., & Semenova, E. V. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-129-139 · Cited by 4
Early phase cancer clinical trials: design, ethics and future directions
Coupe, N. A., Gupta, A., & Lord, S. (2015) · British Journal of Hospital Medicine · doi:10.12968/hmed.2015.76.7.409 · Cited by 3
“Although no deaths occurred, all six patients developed multiorgan failure, two required mechanical ventilation and the worst affected had several fingers and toes amputated (Suntharalingam et al, 2006).”
BackgroundMous, R., Savage, P. M., Eldering, E., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802195430 · Cited by 3
“More importantly, full activation of the total pool of CMVpp65-reactive CTL at once might even result in a cytokine storm as a side-effect [14,38].”
BackgroundHow Can Institutional Review Boards Best Interpret Preclinical Data?
Lavery, J. V. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001011 · Cited by 4
“Six healthy volunteers were given the test agent, TGN1412 (an immune modulator), which triggered a cytokine storm and subsequent multiple organ failure, even at a fraction of the dose found to be safe in macaque monkeys [2].”
BackgroundAssessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Guo, Y., Hill, A. A. V., Ramsey, R., Immermann, F. W., Corcoran, C., Young, D. A., LaVallie, E. R., RYAN, M. S., Bechard, T., Pfeifer, R. W., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-50 · Cited by 3
“failure associated with cytokine storm was observed in all treated volunteers [15].”
BackgroundGenetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy
Jakóbisiak, M., & Gołąb, J. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0091-0 · Cited by 3
“…activation signals through the inclusion of costimulatory molecules should be approached with caution as this could result in severe toxic effects, similar to those which were recently observed following application of agonistic anti-CD28 monoclonal antibodies (Suntharalingam et al. 2006).”
BackgroundRecombinant proteins in rheumatology – recent advances
Rothe, A., & RUBBERT, A. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.019 · Cited by 3
Determination of the Efficiency of First Time-In-Man Designs in Healthy Volunteers
Chu, H., Zha, J., Roy, A., et al. (2008) · Clinical Research and Regulatory Affairs · doi:10.1080/10601330802320955 · Cited by 3
Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases
Angyal, A., Prechl, J., & Sármay, G. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.691 · Cited by 4
Paintaud, G., Diviné, M., Lechat, P. P., Bagot, M., Boucot, I. H., d’Andon, A., Grudé, F., Lecomte, T., Liu-Léage, S., Olive, D., et al. (2012) · Therapies · doi:10.2515/therapie/2012043 · Cited by 5
“[14] Suite à l’affaire Tegenero (défaillances multiviscérales aiguës survenues chez des volontaires sains ayant reçu un AcMo anti-CD28 agoniste),[15] l’ex-Afssaps[16] puis l’EMA[17] ont publié des recommandations pour atténuer les risques d’effets indésirables lors de la 1ère administration à l’homme d’un médicament i…”
Asthma treatments: new and emerging therapies
Calhoun, K. H. (2015) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21611 · Cited by 3
Justification of participation of human subjects in Phase 1 clinical trials: an ethical analysis
Memon, I. U. (1970) · Bangladesh Journal of Bioethics · doi:10.3329/bioethics.v2i2.9543 · Cited by 3
Biotherapeutic first-in-human dose selection: making use of preclinical markers
Johnson, D. E. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.5 · Cited by 3
Conditions involving release of pro-inflammatory cytokines predispose to ARDS
Eisenhut, M. (2007) · European Journal of Anaesthesiology · doi:10.1017/s026502150700049x · Cited by 3
“Transfusion of an anti-CD28 monoclonal antibody into human volunteers stimulated T-cells to release large amounts of these two cytokines and led to pulmonary oedema in all subjects of this trial [4].”
BackgroundProblematic, severe asthma in children: a new concept and how to manage it
Bush, A. (2010) · Acta medica Lituanica · doi:10.15388/amed.2010.21692 · Cited by 2
Azuma, H., Isaka, Y., Nomi, H., Inamoto, T., Li, X., Hőunig, T., Takabatake, Y., Ichimaru, N., Ibuki, N., Matsumoto, K., et al. (2010) · Transplantation · doi:10.1097/tp.0b013e3182007b59 · Cited by 3
Tumor-targeted costimulation by using bi-specific aptamers
Pastor, F. (2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1333 · Cited by 3
“And CD28 superagonist antibodies have elicited lethal cytokine storms in phase-I clinical trials [8].”
BackgroundBush, A. (2008) · Chronic Respiratory Disease · doi:10.1177/1479972308096979 · Cited by 3
Aagaard, A. W., Purdy, S., & Philpott, S. M. (2010) · Cited by 6
The Past, Present, and Future of Chemical Risk Assessment
Limonciel, A. (2014) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-0521-8_1 · Cited by 4
Takimoto, C. H. M., & Wick, M. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385471-1.00031-3 · Cited by 3
Antibody-Dependent Enzyme Prodrug Therapy (ADEPT)
Beǵent, R. H. J., Sharma, S. K., & Chester, K. A. (2010) · Springer eBooks · doi:10.1007/978-3-642-01144-3_28 · Cited by 3
“cellular mechanisms, which are too potent to be tolerable if they are activated systemically ( Suntharalingam et al. 2006 ).”
BackgroundBelmar, N. A., Chan, S. W., Fox, M., Samayoa, J. A., Stickler, M. M., Tran, N., Akamatsu, Y., Hollenbaugh, D. L., Harding, F., & Alvarez, H. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601512 · Cited by 3
Hypersensitivity Reactions to Monoclonal Antibodies
Liu, A. Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48551-7.00020-1 · Cited by 3
Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome
Abugroun, A., Ahmed, C., & Rodriguez, G. (2018) · Case Reports in Oncological Medicine · doi:10.1155/2018/6291614 · Cited by 3
“In 2006, the first human clinical trial of TGN1412 monoclonal antibody to treat rheumatologic disease was conducted, and it was proposed that all 6 volunteers participated had fatal outcome from TGN1412-induced cytokine storm [11].”
BackgroundAnimal models: bridging cross-species variation through animal biotechnology
Laaldin, N., Baloch, S. R., Noor, A., Aziz, A., Gul, A., Rajput, T. A., & Babar, M. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816352-8.00008-4 · Cited by 6
Enhancing the antitumor potency of T cells redirected by bispecifc antibodies
Chang, C., & Goldenberg, D. M. (2017) · Oncoscience · doi:10.18632/oncoscience.366 · Cited by 3
Bush, A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1984-0.00048-6 · Cited by 3
Stančič, B., Qvarfordt, B., Berglund, M. M., Brenden, N., Sydow‐Báckman, M., Fransson, M. E., Nordling, S., & Magnusson, P. U. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107237 · Cited by 3
“TGN1412 was studied as this anti-CD28 superagonist induced a severe systemic inflammatory response in the recipients of a first-in-man Phase I clinical trial [2].”
InfluentialNewland, A. C., & McDonald, V. (2021) · Annals of Blood · doi:10.21037/aob-20-55 · Cited by 3
“Nevertheless, it has been shown that the CD28 agonistic IgG4 mAb, TGN1412, via residual interactions with high affinity FcγR induced T-cell proliferation leading to the cytokine storm (106).”
BackgroundFukaya‐Shiba, A., Otsuka, K., Sasaki, H., Shikano, M., & Wakao, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756870 · Cited by 3
Ethical Considerations in Hydrocephalus Research That Involves Children and Adults
Williams, M. A. (2011) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-0923-6_3 · Cited by 3
Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics
de Haan, L. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_10 · Cited by 3
“mAbs (Suntharalingam et al. 2006).”
Depletion of Gut-Resident CCR5 + Cells for HIV Cure Strategies
Merriam, D., Chen, C., Méndez‐Lagares, G., Rogers, K. A., Michaels, A. J., Yan, J., Casaz, P., Reimann, K. A., Villinger, F. J., & Hartigan-O’Connor, D. J. (2017) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0159 · Cited by 3
“Treatment with single-specificity monoclonal antibodies has led to lymphopenia in some patients.(42,43) Lymphopenia has also been identified as a common adverse side effect of bispecific antibodies such as Blinatumomab, a bispecific antibody that engages CD3 and CD19 for treating B cell lymphomas.”
Cytokine release syndrome. Reviewing a new entity in the intensive care unit
García‐Roche, A., Lagares, C. D., Élez, E., & Ferrer, R. (2019) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2019.01.011 · Cited by 5
Differentiation between Desired Immunomodulation and Potential Immunotoxicity
Bussiere, J. L., & Mounho, B. J. (2008) · doi:10.1002/9780470386385.ch14 · Cited by 3
Relevant Immune Tests across Different Species and Surrogate Models
Bussiere, J. L. (2008) · doi:10.1002/9780470386385.ch15 · Cited by 3
Companies Claim to Fame and their scientific challenges in vaccine development
Boon, L. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.11.014 · Cited by 3
Use of Animal Models of Disease in the Preclinical Safety Evaluation of Biopharmaceuticals
Koppele, J. M. T., & Witkamp, R. F. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse172 · Cited by 3
Principles of Systemic Therapy
Tidman, M. J., & Smith, C. H. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0019 · Cited by 6
Burns‐Naas, L. A., & Pallardy, M. J. (2013) · Wiley eBooks · doi:10.1002/9781118517000.ch17 · Cited by 4
CD28-Selective Inhibition Prolongs Non-Human Primate Kidney Transplant SurvivalPreprint
Lovasik, B. P., Kim, S. C., Higginbotham, L. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.03.539333 · Cited by 3
“Prior efforts to translate targeted CD28 therapy to human clinical trials were halted when the superagonist mAb TGN1412 resulted in cytokine storm and multi-organ failure in six healthy human volunteers in a 2006 Phase I clinical trial (14).”
BackgroundMallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070824 · Cited by 2
“The failure stemmed from fundamental immunological differences: the distribution of the CD28 receptor on effector memory T cells in humans versus non-human primates produced a qualitatively different pharmacological response [54,71,72].”
Yuan, L., Kulkarni, M. M., Chiswick, E. L., Koh, C. M., Sandy, P., Nabhan, S., Sherman, W., Johnson, M. L., Wang, J., Falchook, G. S., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70067 · Cited by 2
“8 The therapeutic window of immune agonists is generally narrow, 9,10 making the choice of starting dose and escalation scheme critical for Phase I safety and success in identifying the maximum tolerated dose.”
Relinquishing experimental control to improve translation
Wallis, J. M. (2025) · Synthese · doi:10.1007/s11229-025-05219-9 · Cited by 2
Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell Activation
Thisted, T., Smith, F. D., Jiang, Z.-G., Biesová, Z., Onumajuru, A. M., Kleschenko, Y., Malhotra, K., Saxena, V., Mukherjee, A., & van der Horst, E. H. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0535 · Cited by 3
Park, J. C., Curti, B. D., Butler, M. O., Wehrenberg-Klee, E. P., Elassal, J., Tighe, R., Battula, S. K., Iodice, G. M., Kaufman, H. L., & Kirkwood, J. M. (2025) · Nature Communications · doi:10.1038/s41467-025-63579-9 · Cited by 7
Zimmermann, T., Philipp, E., Marget-Muller, S., Leclercq-Cohen, G., Golling, S., Siebourg‐Polster, J., Augustin, A., & Villenave, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-30375-w · Cited by 2
“They recur across more common vascular-leak states, including sepsis/ARDS 72,73 , cytokine-release syndromes after cellular immunotherapy 74,75 or immunomodulatory drugs 76 , viral infections such as dengue 77,78 , and idiopathic/systemic capillary leak syndrome 79,80 .”
Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma
van Gelder, T., Baan, C. C., Vincenti, F. G., & Mannon, R. B. (2013) · Transplant International · doi:10.1111/tri.12140 · Cited by 2
“However, the use of this drug in man has been associated with marked cytokine release [8].”
BackgroundTreatment of autoimmune disease: time for a paradigm shift?
Mor, F. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0002-1 · Cited by 2
Khansari, N. (2015) · MOJ Immunology · doi:10.15406/moji.2015.02.00062 · Cited by 2
“In a phase I clinical trial, agonistic anti-CD28 monoclonal antibody (TGN142) induced cytokine-release syndrome in healthy volunteers due to strong activation of T cells and subsequent release of plentiful amount of pro-inflammatory cytokines [52].”
BackgroundChemotherapy and Novel Cancer Targeted Therapies
Ronghe, M., & Murphy, D. (2016) · Springer eBooks · doi:10.1007/978-3-662-48590-3_9 · Cited by 1
Percellome toxicogenomics project as a source of biomarkers of chemical toxicity
Kanno, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00061-0 · Cited by 2
Feddema, J. J., & Claassen, E. (2018) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20184397 · Cited by 5
“Analysis of CTs in Asia revealed a late-stage pipeline with a high number of phase 3 studies compared to phase 1 studies, which is the opposite of what could be expected considering the phase transition success rates and risk of failure.20 This underrepresentation of phase 1 studies could be because many potential res…”
BackgroundNugent, P., Duncan, J. N., & Colagiovanni, D. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00008-6 · Cited by 2
Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins
Kirk, A. D. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4096-3.00020-9 · Cited by 3
A CTSA One Health Alliance guidance on institutional review of veterinary clinical studies
CTSA One Health Alliance, Moore, S. A., O’Kell, A. L., Borghese, H., Garabed, R. B., O’Meara, H., & Baneux, P. J. R. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02790-4 · Cited by 3
CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade
Sundqvist, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670864 · Cited by 2
“OKT3 induces self-limited cytokine release and spontaneously reversible clinical symptoms (31), similar to but less pronounced than the TGN1412-induced life-threatening stereotypic symptoms in all individuals (10).”
BackgroundResultInfluentialCurrent Research Trends in Cytokine Storm: A Scientometric Study
Wang, Q., Cui, Y., Wang, K.-T., Xu, D. W., Wang, Y., Dong, X., Tang, J., Wang, Y., Qiao, T., & Zhang, H. (2022) · Current Drug Targets · doi:10.2174/1389450123666220414135249 · Cited by 2
Managing Severe Adverse Reactions to Biologicals in Severe Asthma
Bălan, R.-G., Deleanu, D. M., Pintea, I., Dobrican, C. T., Man, M. A., Bocșan, I. C., & Muntean, I. A. (2023) · Biomedicines · doi:10.3390/biomedicines11123108 · Cited by 2
Awuah, D., Li, L., Williams, L., Urak, R. Z., Kujawski, M., Forman, S. J., Shively, J. E., & Wang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-47115-7 · Cited by 2
“For instance, clinical administration of an anti-CD28 antibody to healthy individuals in a phase one study resulted in peak levels of inflammatory cytokines TNF-α, IL-2, -6 and -10 as well as IFN-γ, and IL-1β within the first few hours of infusion 33 .”
BackgroundRoelcke, V. (2022) · Science in Context · doi:10.1017/s0269889723000170 · Cited by 5
“The clinical course of the events is described in detail in Suntharalingam et al. 2006.”
BackgroundMethodSpecies Selection for Pharmaceutical Toxicity Studies
Harvey, W. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_133 · Cited by 5
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology
Kwon, H., & Lee, C. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.005 · Cited by 2
Edwards, B. D., Bégaud, B., Daemen, E., Dokas, Ι. M., Fishbein, J. M., Greenberg, H. E., Hochberg, A. M., Louët, H. L., Lyngvig, J., Mogles, N. M., et al. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13353 · Cited by 2
GLP: A requirement in cell therapies - perspectives for the cardiovascular field
Ruch, U., Skorska, A., Lemcke, H., Steinhoff, G., & David, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.003 · Cited by 4
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0005 · Cited by 2
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_2 · Cited by 3
Unerwünschte Arzneimittelreaktionen der Haut: Was gibt es Neues?
Treudler, R., & Simon, J. C. (2012) · Der Internist · doi:10.1007/s00108-012-3057-y · Cited by 2
Immunmodulierende Antikörper in der Dermatoonkologie
Schrama, D., Hauschild, A., & Becker, J. C. (2008) · Der Hautarzt · doi:10.1007/s00105-008-1539-6 · Cited by 2
Aufgaben der öffentlich-rechtlichen Ethikkommissionen in der Bundesrepublik Deutschland
Rittner, C. K. (2007) · Rechtsmedizin · doi:10.1007/s00194-007-0449-8 · Cited by 2
Ritter, J. M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03806.x · Cited by 2
Die richtige Rekrutierung von Studienteilnehmern
Grün, B., & Haefeli, W. E. (2009) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-009-0822-8 · Cited by 2
Garzone, P. D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369417-1/50072-9 · Cited by 2
Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers
Radhakrishnan, V. S., Swanson, M. S., & Sinha, U. K. (2015) · AIMS Medical Science · doi:10.3934/medsci.2015.4.347 · Cited by 2
Avolio, M., Caracciolo, S., Tosti, G., Vollero, L., Fiorentini, S., & Caruso, A. (2008) · Viral Immunology · doi:10.1089/vim.2007.0095 · Cited by 2
“The crucial role of CD28 stimulation in the production of proinflammatory cytokines has been recently highlighted by dramatic systemic inflammatory response syndrome induced in healthy volunteers by the administration of an anti-CD28 mAb (40).”
Real-time Cytotoxicity Assays in Human Whole Blood
Hsiao, C.-W., Lo, Y.-T., Liu, H., & Hsiao, S. C. (2014) · Journal of Visualized Experiments · doi:10.3791/51941 · Cited by 2
Milbrandt, E. B., Ishizaka, A., & Angus, D. C. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2601004 · Cited by 3
Rosenzweig, M. A., Seldin, D. C., Remick, D. G., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.94 · Cited by 2
Biotherapies: Are they Just Like any Other Drugs?
Paintaud, G., Tonelli, D., Postaire, E., Amalric, F., Bassompierre, F., Becquemont, L., Cartron, G., Cellier, D., Dagher, G., Demerens, T., et al. (2007) · Therapies · doi:10.2515/therapie:2007041 · Cited by 2
“The example of TGN1412 (from TeGenero), which induced serious adverse effects in healthy subjects during a phase 1 study[2]”
BackgroundRacial disparities in clinical trial enrolment
Gross, C. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61714-6 · Cited by 2
Clinical Trial Design in Prevention and Treatment of Acute Respiratory Distress Syndrome
Curley, G. F., & McAuley, D. F. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2014.08.009 · Cited by 3
Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes
Morillon, Y. M., Martin, A. J., Gojanovich, G. S., Wang, B., & Tisch, R. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0336-z · Cited by 2
“inducing transplantation tolerance (Ford et al. 2014; Suntharalingam et al. 2006).”
Paintaud, G., Diviné, M., Lechat, P. P., Bagot, M., Boucot, I. H., d’Andon, A., Grudé, F., Lecomte, T., Liu-Léage, S., Olive, D., et al. (2012) · Therapies · doi:10.2515/therapie/2012046 · Cited by 3
“[14] Further to the Tegenero incident (acute multiple organ failure occurring in healthy volunteers having received an agonist anti-CD28 MoAb),[15] the ex-Afssaps (at present Effector C1”
BackgroundSafety evaluation of biotechnology-derived pharmaceuticals
Inoue, T., & Yasugi, K. (2011) · Drug Delivery System · doi:10.2745/dds.26.622 · Cited by 2
Costimulatory blockade: A novel approach to the treatment of glomerular disease?
Esposito, P. B., Rampino, T., & Canton, A. D. (2015) · World Journal of Methodology · doi:10.5662/wjm.v5.i2.20 · Cited by 2
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.